Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012
K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004
Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001
p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005
The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019
Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer Source: Eur Respir J 2011; 38: 903-910 Year: 2011
Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011
Biological analysis of the single codon deletion in Exon 19 of EGF receptor in non-small cell lung cancer responsive to gefitinib Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011